Antibiotics for MDR/XDR Gram-Negative Infections

A novel class of octapeptin derivatives with improved activity against multiple gram-negative bacteria strains.

Novel lipopeptide antibiotics that targets the most critical pathogens identified by WHO; Greater efficacy with significantly reduced nephrotoxicity

  • Infection prevention
  • Antimicrobial compound/strategy

  • Bacteria

  • Human
  • Veterinary

Development stage:
  • Research
  • Development

  • Academia

  • License, Co-develop

Funding organisation:
  • CARB-X

Infectious disease area:
  • UTI
  • STI
  • BSI
  • RTI

Geographic origin:
  • Oceania

UniQuest Pty Limited is The University of Queensland’s commercialisation company

Potential for these novel lipopeptides as a “resistance breaker” to synergise with existing antibiotics to potentiate their activity against MDR/XDR bacteria

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!